Verve Therapeutics, Inc.

NasdaqGS:VERV Stok Raporu

Piyasa değeri: US$501.8m

Verve Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Verve Therapeutics's earnings have been declining at an average annual rate of -32.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 121.2% per year.

Anahtar bilgiler

-32.4%

Kazanç büyüme oranı

59.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı121.2%
Özkaynak getirisi-35.3%
Net Marj-933.0%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Aug 30

Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

Aug 10
Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Jul 12
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Nov 09
We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics: Cathie Wood Adds To ARKK

Sep 20

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Aug 23

Verve Therapeutics falls postmarket on $200M stock offering

Jul 20

More CRISPR In Human Subjects

Jul 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31
Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

Gelir ve Gider Dağılımı

Verve Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:VERV Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2421-193530
31 Mar 2416-197520
31 Dec 2312-200500
30 Sep 238-193490
30 Jun 235-192470
31 Mar 233-179430
31 Dec 222-157380
30 Sep 221-148330
30 Jun 220-12529-25
31 Mar 220-13724-11
31 Dec 210-120190
30 Sep 210-1131416
30 Jun 210-991048
31 Mar 210-53740
31 Dec 200-4650

Kaliteli Kazançlar: VERV is currently unprofitable.

Büyüyen Kar Marjı: VERV is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VERV is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.

Büyüme Hızlandırma: Unable to compare VERV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: VERV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: VERV has a negative Return on Equity (-35.28%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin